ArticleFrontiers in medicine2025
Effectiveness and safety of electroacupuncture in female overactive bladder: a randomized controlled trial investigating sacral and tibial nerve modulation.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overactive bladder (OAB) is a common condition in women, affecting quality of life with symptoms like urgency, frequency, and nocturia. Current treatments, such as antimuscarinic drugs, have side effects that limit their effectiveness. Electroacupuncture (EA) shows promise as an alternative, but its mechanisms and effectiveness for OAB are not fully understood. Objective: This blinded, randomized controlled trial aimed to evaluate the efficacy and safety of electroacupuncture as a therapeutic intervention for female patients with OAB and to explore potential mechanisms involving the sacral and posterior tibial nerves. Methods: Sixty-eight female OAB patients were stratified and randomized into two groups. One group received EA treatment at BL33 and SP6 acupoints three times weekly for 4 weeks, while the control group received tolterodine, a standard antimuscarinic medication. Outcome measures included urgency symptoms, Overactive Bladder Symptom Score (OABSS), and quality of life at 2 and 4 weeks post-treatment, as well as at a 3-month follow-up. Safety and acceptance of EA were also assessed. Additionally, urinary cytokine levels were analyzed to investigate the neurobiological impact of the treatments. Results: No significant baseline differences were observed between the groups. At 2 weeks, EA significantly improved quality of life scores ( Conclusion: Electroacupuncture at BL33 and SP6 is a promising, well-tolerated, and effective intervention for OAB, supporting its integration into treatment paradigms. Further research is needed to optimize its clinical application. Clinical trial registration: clinicaltrials.gov, identifier ChiCTR-1900021372.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.